1. Home
  2. SANM vs ABVX Comparison

SANM vs ABVX Comparison

Compare SANM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanmina Corporation

SANM

Sanmina Corporation

HOLD

Current Price

$218.55

Market Cap

13.3B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$98.50

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANM
ABVX
Founded
1980
2013
Country
United States
France
Employees
N/A
N/A
Industry
Electrical Products
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
11.9B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
SANM
ABVX
Price
$218.55
$98.50
Analyst Decision
Buy
Buy
Analyst Count
3
13
Target Price
★ $155.00
$131.31
AVG Volume (30 Days)
479.0K
★ 1.2M
Earning Date
04-27-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 14.07
N/A
EPS
★ 4.71
N/A
Revenue
★ $7,890,475,000.00
N/A
Revenue This Year
$74.61
$52.14
Revenue Next Year
$13.43
$4,132.27
P/E Ratio
$46.91
★ N/A
Revenue Growth
★ 16.78
N/A
52 Week Low
$113.71
$69.81
52 Week High
$288.68
$148.83

Technical Indicators

Market Signals
Indicator
SANM
ABVX
Relative Strength Index (RSI) 59.62 34.28
Support Level $213.47 $74.79
Resistance Level $230.56 $130.96
Average True Range (ATR) 9.85 4.47
MACD 2.52 -1.17
Stochastic Oscillator 73.07 11.16

Price Performance

Historical Comparison
SANM
ABVX

About SANM Sanmina Corporation

Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense, and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue mainly in the United States, China, and Mexico, but has a presence around the world.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: